Patients with acute coronary syndrome (ACS) are at maximal risk of recurrent events in the initial few weeks following the index coronary event, with some studies suggesting that the risk may be as high as 20 % [1]. Rapid reduction of low-density lipoprotein cholesterol (LDL-C) has been shown to reduce disease progression, reduce the risk of future ischemic events, lower morbidity and mortality in these patients [2]. Consequently, all major global guidelines recommend the in-hospital initiation of high-intensity statin therapy to prevent these early ischemic events [3].
